Related Experiment Video
Updated: Jul 4, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Serum BAFF expression in patients with myasthenia gravis
Jee Young Kim1, Young Yang, Joon-Shik Moon
1Department of Neurology, Ewha Womans University College of Medicine, Republic of Korea.
Journal of Neuroimmunology
|July 1, 2008
Summary
Serum levels of B-cell activating factor (BAFF) were elevated in myasthenia gravis (MG) patients compared to healthy individuals. This suggests BAFF may contribute to the autoimmune mechanisms underlying MG.
Area of Science:
- Immunology
- Autoimmune Diseases
- Neuroimmunology
Background:
- Myasthenia gravis (MG) is a characteristic antibody-mediated autoimmune disorder affecting neuromuscular transmission.
- B-cell activating factor (BAFF), a member of the tumor necrosis factor (TNF) superfamily, is crucial for B-cell survival and maturation.
- Dysregulation of B-cell function is implicated in the pathogenesis of various autoimmune diseases.
Purpose of the Study:
- To investigate whether serum levels of BAFF are elevated in patients diagnosed with myasthenia gravis.
- To explore the potential role of BAFF in the immunopathogenesis of MG.
Main Methods:
- Serum samples were collected from 40 patients with myasthenia gravis and 30 age- and sex-matched healthy controls.
- Serum BAFF levels were quantified using a standardized immunoassay technique.
- Statistical analysis was performed to compare BAFF levels between the MG patient group and the healthy control group.
Main Results:
- Serum BAFF levels were found to be significantly higher in the group of MG patients compared to the healthy control group.
- The elevated BAFF levels in MG patients suggest a potential link between BAFF and the disease state.
- No correlation analysis with disease severity or subtypes was performed in this initial study.
Conclusions:
- The findings indicate that elevated serum BAFF levels are associated with myasthenia gravis.
- BAFF may play a significant role in the autoimmune processes contributing to the development or progression of MG.
- Further research is warranted to elucidate the precise mechanisms of BAFF involvement in MG, including its impact on B-cell and T-cell activation.
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...